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Catherine Heidi Seage, PhD1 and Lenira Semedo, PhD2
Abstract
Pernicious anemia (PA) is a chronic condition that is usually treated using B12 injections. Due to the pandemic, many patients
were prescribed an alternative oral B12 treatment. There is limited evidence that this is effective at managing symptoms of PA.
The aim of this study was to document treatment changes across the United Kingdom and the impact on patient experience.
An online survey explored how the treatment of PA has been managed during the early stages of the pandemic; responses
were analyzed for a subsample of participants receiving prescribed B12 injections and where changes in treatment applied
(n ¼ 329) using content analysis. The most common reported change was the suspension of injections, with oral B12 being
offered as an alternative treatment. Patients were concerned about the long-term impact that changes would have on their
condition management, and many stated that they were dissatisfied with the level of care received. Those who were supported
by health care providers to continue their usual treatment reported experiencing improved health and well-being. This study
highlights the major impact of treatment changes on patient health outcomes and the need to further support health care
professionals with PA management during and beyond the pandemic.
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Pernicious anemia (PA) is an autoimmune condition where
the body fails to absorb vitamin B12 (Cobalamin) in the
intestine, which has serious implications for its sufferers.
The prevalence of PA worldwide may range between 50 and
4000 cases per 100 000; however, this may vary due to the
complexity of diagnosis (1). In the United Kingdom, it is
estimated that PA incidence varies between 1 and 5 in 100
000 cases per year (2). Pernicious anemia is commonly
treated by regular quarterly B12 injections (hydroxocobala-
min) which are administered in primary care. Due to Coro-
navirus disease 2019 (COVID-19), primary care services
have adapted to reduce the number of face-to-face consulta-
tions. In recent weeks, many patients with PA have been
moved to alternative treatments which use oral B12 in tablet
form. However, there is a debate that this oral replacement is
not effective at managing PA where absorption and neuro-
logical manifestations may be an issue (3). Current guidance
from the British Society for Hematology is to offer oral B12
(cyanocobalamin) as a replacement treatment, however,
where possible to continue treating using B12 injections (4).
Recently, the Pernicious Anaemia Society, a nonprofit
support group for individuals with PA, has been inundated
with requests from individuals who are concerned about the
long-term health consequences of being unable to receive
their usual treatment (5). The type of treatment being offered
is dependent on the provision within individual primary care
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settings. The extent to which PA treatment has been
impacted in the United Kingdom is unknown. An online
survey was designed to capture individual’s experience of
PA treatment change during the COVID-19 pandemic. Spe-
cific objectives of this study are to (1) establish the extent to
which treatment for PA has changed across the United King-
dom, (2) to explore respondents’ perceptions on how
changes to treatment have been managed within their pri-
mary care setting, and (3) to document whether patients have
made any changes to how they manage their PA.
Methods
The current study received ethical approval from the School
of Sport and Health Science Ethics Committee, Cardiff Met-
ropolitan University (reference STa-2872). This study
employed a cross-sectional survey design. An online survey
was developed to collect patients’ experiences during the pan-
demic. Survey development was informed by current litera-
ture and a recent change in guidelines regarding the treatment
of PA (4). This study aligns with the recent UK Patient and
Public Involvement (PPI) Standards for research in terms of
inclusive opportunities, working together and impact (6).
Patient and Public Involvement input was gained through the
PA society, 2 members were consulted from the early stages
of research to ensure involvement from those who may benefit
from the research (inclusive opportunities), to confirm the
survey questions were clear and understandable (working
together) as well as to support the dissemination of study
results (impact). Eligible participants were those aged over
18 with a confirmed PA diagnosis and who were currently
receiving prescribed treatment for their PA as a resident in the
United Kingdom. Participants were recruited via online social
media platforms including Facebook and Twitter, and the
survey link was also sent out to members of the Pernicious
Anaemia Society. The survey contained 15 items which were
a mixture of closed questions and open-text responses (Sup-
plementary 1). The first section of the survey collated demo-
graphic information about the respondents as well as clinical
information about their PA. Participants were asked about
how their PA is typically treated, and if this has changed
during the COVID-19 pandemic.
Data Analysis
Survey data were analyzed using descriptive statistics, open-
text responses were analyzed using content analysis (7–9)
and managed through NVivo (Version 12) (10) through 1)
familiarizing with the data, 2) identifying and condensing
meaningful units within responses, 3) generating codes, and
4) developing categories within themes. Both authors, inde-
pendently coded all the data to inductively generate themes
accurately reflecting the data. Themes were revised and dis-
cussed, and where there were discrepancies (eg, code names)
these were resolved by consensus to reach final themes (11).
Any differences and commonalities in treatment changes
across the United Kingdom were documented. Quotes were
selected to portray identified themes.
Results
The online survey was live on google forms between June
26, 2020, and October 5, 2020, and was completed by
patients across the United Kingdom. In total, there were
683 responses to the survey; of these, 329 participants indi-
cated that they had experienced a change to their prescribed
treatment, which was a consequence of the pandemic. All
reported percentages are based on this subsample of partici-
pants. Table 1 provides an overview of the key demographic
and clinical characteristics of this sample.
Participants’ ages ranged from 23 years to 87 years, and
mean reported age was 53.41 + 13.24. There were 275
females and 52 males; one participant identified as nonbinary
and one did not disclose gender. Nearly half of the participants
were members of a support group to help them manage their
condition. All United Kingdom countries were represented in
the data, but most responses were from England (58.05%).
Prior to the pandemic, all patients were receiving prescribed
treatment in the form of prescribed hydroxocobalamin injec-
tions which were typically administered within a health care
setting every 8 to 12 weeks. Twenty-one respondents indi-
cated that they self-administered B12 injections which they
purchased alongside prescribed treatment; this was because
they perceived the frequency of prescribed injections to be
insufficient to manage their symptoms.









40-59 years 161 48.94
60þ years 113 34.35
Missing 8 2.43
Standard treatment
Prescribed B12 injections within health care
setting
305 92.70
Prescribed B12 injections to self-administer
at home
3 0.9
Prescribed B12 injections and “top-up” at home 21 6.3
Frequency of usual treatment





Northern Ireland 8 2.25
Scotland 75 22.79
Location not disclosed 5 1.51
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Treatment Changes During the Pandemic
Precautionary measures to deal with the pandemic meant
that treatment had changed for many respondents. Changes
were experienced mainly by those whose usual care was to
have prescribed B12 administered within a health care set-
ting. The types of treatment changes made were consistent
across the United Kingdom with no apparent differences
between countries. Decisions to change treatment were
mostly initiated by a health care professional with no further
discussion with the patient (n ¼ 276). However, for some
patients, these changes took effect after a mutual discussion
between the patient and their health care provider (n ¼ 42).
A small number of individuals requested that they be pro-
vided an alternative treatment (n ¼ 4). Often changes were
temporary with patients being informed that their health care
provider would revert to standard care once it was safe to do
so (n ¼ 152). A small proportion of patients had been told
that treatment changes were permanent (n¼ 32). Nearly half
of respondents stated that they were unsure how long the
change to their treatment would last (n ¼ 143). In most
cases, treatment changes meant patients’ injections had been
suspended and replaced with B12 tablets and nutritional
advice provided. The data analysis identified 8 themes
related to treatment changes, which are summarized in
Table 2.
Change in Frequency of Prescribed Injections
Patients who continued to receive their injections from their
health care provider were often required to wait longer to
receive their scheduled injections. Some patients were asked
to attend a different surgery with social distancing measures
in place, while others were asked to wait until their symp-
toms got worse before contacting their surgery to arrange
their appointment.
Table 2. United Kingdom Treatment Changes Due to COVID-19 With Frequencies of Codes.a
Themes Participant quotes Frequency
Injections at a GP surgery with changed
frequency or change to location
Had letter from GP saying reduced to 12 weekly rather than the offered 8 weeks.
(P45, England)
I was sent to a different surgery for my injection and was told it was because
distancing was easier there. (P7, England)
46
Injections prescribed for self-treatment Much to my surprise, a few weeks ago, a GP called me and said that I could self-
administer the injections every four weeks if I were happy to be trained in how
to do that. I went for an appointment with the practice nurse where she trained
me and I have been giving myself the injections since then. (P11, England)
I was asked if I was happy to inject myself, and as I am a nurse I was pleased with this
arrangement. (P14, England)
37
Injections replaced with oral B12 (tablets)
on prescription
My injections were cancelled and the DR prescribed B12 tablets, even though with
PA my body can’t absorb B12 from the tablets! (P4, Northern Ireland)
I receive regular injections at the GP surgery every 8 weeks. After lockdown I was
told I could not receive my injections at all and was given a “prescription” for
low-grade poor-quality capsules and told to take 8 per day. Not only did these
capsules upset my stomach there was a gradual decline in my health and B12
symptoms returned. (P126, Scotland)
78
Patients advised to purchase own B12
supplement
It’s been completely stopped. Told to take a B12 supplement from a health food shop.
When I have no way of absorbing it in the gut! (P46, Wales)
28
Request to undergo further diagnostic tests I was told last week due to Covid that I can’t have it[injections]. Now after phoning
today I’m told one doctor is looking at everyone who receives a B12 injection is
being referred to one doctor for blood tests to see if we still need it. (P84,
Scotland)
Had to fight with GP to continue[injections], at present awaiting blood results to see if
injection will be stopped or continues (P45, Wales)
19
No treatment received from GP surgery Treatment was completely stopped from the start of lockdown until late June and I was
not offered any alternative (P19, Wales)
121
Impact of treatment changes on symptoms Fatigue increased, fuzzy brain, forgetfulness especially mid-sentence, jumbled up
words (P3, Northern Ireland)
. . . feel so dizzy and nauseous, bad tempered and can’t remember words. (P18,
Scotland)
195
Emotional impact of treatment changes Let down, undervalued, left to become ill regardless of the consequences for me
or my family. (P59, England)
Extremely disappointed. GPs don’t seem to understand or respect how the lack
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I was told to wait another four weeks to see if pins and needles
got worse/if I really needed it. When I called to speak to the GP
he said he would have to make an “extreme exception” and that I
was lucky as I would be the only person in the practice. (P184,
England)
Injections Prescribed for Self-Treatment
It was common for patients whose injections had been sus-
pended to request to self-treat at home. These injections
would be administered by themselves, a family member, or
a friend who is a health care professional. GPs supported this
process by ensuring individuals were trained to safely
administer B12 injections at home. Patients who had been
enabled to self-treat (n ¼ 37) embraced the change to their
treatment and preferred this to standard treatment. The
increased perceptions of control over treatment are illu-
strated in the quote:
Self-injecting was as quite liberating as I am now not tied to
visiting the surgery so frequently. (P2, England)
However, some requests to self-treat were not supported;
in desperation to receive replacement B12, these patients
began to source their own injections privately or administer
hydroxocobalamin injections bought overseas without a pre-
scription (n ¼ 12).
I used to have my injection at the surgery, but when Covid came
stopped my injections so I purchased online and now self-inject.
(P212, Wales)
Individuals who decided to self-treat were often able to
administer injections at a treatment schedule that was more
based on individual need. This group reported a noticeable
improvement in their symptoms and quality of life.
I now have continual B12 every day and have no symptoms from
week 8 to 12 so my quality of life has improved (P221, England)
, . . . I was very tired, lethargic, my brain felt like mush, hard
to concentrate and breathlessness. Since self-injecting monthly I
now have
none of these symptoms. (P5, England)
Injections Replaced With Oral B12 (Tablets)
on Prescription
Around a quarter of survey respondents had been prescribed
B12 replacement in an oral form. Patients voiced their con-
cerns over the efficacy of this alternative source of B12; it
was unclear if an oral route would be effective at managing a
condition caused by an inability to absorb dietary forms of
B12. There was a perceived lack of evidence for the effec-
tiveness of oral supplementation at controlling symptoms.
Patients felt that the advice given by health care profession-
als about treatment during the pandemic conflicted with their
understanding of the biological basis of the condition. The
lack of confidence in the recommendation to move to oral
supplementation is emphasized in the following quote . . . .
the surgery may just as well have given me a bag of sweets
(P11, England)
Request to Undergo Further Diagnostic Tests
As a result of treatment changes, many patients reported hav-
ing their injection suspended, they had been asked to under-
take blood tests to confirm their need for replacement B12
I was told last week due to Covid that I can’t have it. Now after
phoning today I’m told one doctor is looking at everyone who
receives a B12 injection is being referred to one doctor for blood
tests to see if we still need it. (P652, Scotland)
No Treatment Received From Health Care Setting
In this sample, many respondents reported that their B12
injections had been suspended; they had not received any
form of treatment since the start of the pandemic and had not
been offered an alternative treatment (n ¼ 121). These
patients were angry and anxious; they were concerned that
suspended treatment would lead to long-term neurological
damage. Patients felt this was dangerous, for one individual
the change was viewed as playing Russian Roulette with my
health (P7, Wales).
Impact of Treatment Changes on Symptoms
As a result of the changes in PA treatment and subsequent
delays in getting treatment reinstated, many reported experi-
encing worse and more frequent symptoms which impacted
their quality of life (n ¼ 195).
All my symptoms worsened considerably, and I was struggling
to function with daily activities and work (P144, England)
They [symptoms] are much worse than before and I have
episodes that leave me bed ridden (P26, Scotland).
Those who had been moved to oral B12 noticed the return
of symptoms which they had not experienced since their
initial PA diagnosis.
When put on tablets I developed a shaking/tremor which I
remembered suffering before I was diagnosed, belatedly after
about three years. (P19, England)
Further, a small number of participants mentioned devel-
oping new symptoms. The type of symptoms varied, ranging
from physical to neurological symptoms.
They[symptoms] have become worse and I have new symptoms
(P435, Wales)
I started to experience pins and needles in the fingers of my
right hand. (P45, Scotland)
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Emotional Impact of Treatment Changes
For most individuals, changes to their usual treatment were a
source of fear, anxiety, and distress (Table 3).
Many were dissatisfied with the way in which changes to
treatment had been managed; the lack of shared decision-
making made patients feel left out or overlooked. Only a
small number of respondents reported that the decision to
change their treatment had been made in response to a
mutual discussion with their health care provider. This
absence of shared decision-making made patients feel
powerless.
Upset, angry and deeply worried. I was not consulted and have
had to chase my surgery to find out what is happening at every
stage (P134, England)
Discussion
This study aimed to document changes in prescribed treat-
ment for PA during the COVID-19 pandemic. The survey
revealed that many health care settings had been able to
safely continue to provide patients with their usual treatment
by implementing social distancing measures. These changes
align with the guidance set out by the British Society for
Haematology which states that during the pandemic those
with PA should continue to receive hydroxocobalamin injec-
tions where possible (4). However, despite this recommen-
dation, over half of the survey respondents reported that they
had experienced a change to their usual treatment. For most
patients, this meant that their treatment had been suspended
or that their hydroxocobalamin injections had been replaced
with oral B12. Oral forms of B12 were perceived to be less
effective at managing symptoms.
This survey was able to document patient experiences of
changes to their treatment during the pandemic across the
United Kingdom. While no differences across regions were
identified in terms of treatment changes; the provision of
alternative treatments varied considerably between health
care settings. In some settings, patients had been supported
by their health care provider to self-administer hydroxoco-
balamin injections, while in others prescribed treatment had
been completely withdrawn. The lack of a consistent
approach to managing changes for this patient group has led
to a disparity in patient care. The survey highlighted that it
was common for patients to have been advised to manage
their B12 deficiency through diet or told to purchase dietary
supplements. Some health care providers had requested that
patients have their B12 levels re-tested to confirm their PA
diagnosis and this becomes problematic. Due to the lack of
reliable clinical tests for PA, it is common for this patient
group to have experienced challenging diagnostic journeys
(12–14,), therefore requests to retest may result in additional
patient distress.
The chronicity of PA and the requirement for lifelong
treatment were not always considered when making treatment
changes, and this has disrupted the quality of life of several
patients. Responses emphasized the importance of shared
decision-making and the need to communicate changes in a
way that addresses patients’ concerns about their health (15).
Guidance by the British Society of Haematology also empha-
sizes the importance of discussing treatment changes during
the pandemic (4). Providing patients with the opportunity to
make shared decisions about their health care is empowering;
however, in this sample, few participants had been involved in
discussions of changes that would impact their health care.
Shared decision-making can improve patient satisfaction and
compliance with treatment regimens (15,16). The pandemic
appears to have exacerbated existing patient concerns around
discrepancies in diagnosis and management of PA within
health care settings (17).
Strengths of this research relate to the in-depth account of
peoples’ experiences of PA treatment during the pandemic.
Table 3. Feelings and Emotions Experienced Due to Changes in Treatment With Code Frequencies.
Feelings and emotions Participant quotes Frequency
Acceptance I felt a bit strange but was aware that there would be changes to do with access to surgery
(P36, England)
It is an inconvenience, but I am lucky to still get my treatment (P16, Scotland)
36
Fear Scared, very scared. I already suffer with other illnesses which leave me already feeling unwell, to have
the B12 injections stopped is going to end any sense of a quality of life (P184, England)
. . . frightened as it has taken me many years to get my health on an even keel (P255, England)
69
Angry and upset Very angry. I was told I needed these injections for life and now I’m told I’ll be ok on tablets.
(P70, England)
I’m angry, I’ve had regular injections for 24 years . . . If they weren’t necessary, why was I receiving them.
The GP and nurses seem ill informed and lack even basic knowledge about the difference between
dietary deficiency and PA (P553, Wales)
93
Let down I feel forgotten. Like I have no control over my own health (P525, Wales)
Seriously let down as the GP practice made no attempt to assess the clinical needs of individual patients
to determine whether tablets were a viable alternative. (P57 England)
Deflated, unsupported, like I don’t matter (P84, England)
25
Total 223
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Patient and Public Involvement involvement added value to
the research due to lived experience of the condition. While
we sought a balanced representation of respondents across
the United Kingdom, responses were mainly from England,
which may have limited the generalizability of results.
Although patients would all be treated within the National
Health Service (NHS), the 4 health systems of the United
Kingdom nations are devolved (18). Nevertheless, the homo-
geneity of responses suggests that the views collected in this
survey accurately reflect the issues experienced by people
with a diagnosis of PA who have experienced treatment
changes during the COVID-19 pandemic.
This survey has a few limitations: the use of an online
sample which was recruited in part by third-sector organiza-
tions may have led to potential self-selection bias as individ-
uals who are unhappy with their medical care may be more
likely to engage with support groups (19). It is widely
acknowledged that there is often a delay in diagnosing PA
and that many individuals with nondietary forms of B12
deficiency struggle to receive a clinical explanation for their
symptoms (13,14,17). This survey did not capture the experi-
ences of individuals who have symptoms of nondietary B12
deficiency but are not currently diagnosed with PA. As a
patient group, these individuals are also likely to be
impacted by the pandemic and experience challenges in
accessing treatment.
This study captured patient perception of changes and
although it has improved the understanding of the impact
that the COVID-19 pandemic has had on PA treatment, fur-
ther research is needed to explore these changes from the
perspective of health care professionals. The future direction
of this research is to gauge health care professionals’ views
on the challenges encountered in delivering replacement B12
therapy during the pandemic. This study highlights the need
to further educate health care professionals on the impact of
PA on individuals’ health-related quality of life. Develop-
ment of NICE guidelines on the management of PA would
also provide health care providers with clear indicators on
how to support patient-centered approach to PA
management.
Conclusion
Treatment changes because of the pandemic were perceived
to be suboptimal to treat PA symptoms. This article high-
lights several learning points that can be applied to manage-
ment beyond the pandemic.
 Timely communication of treatment changes would
help patients further understand the reasons why alter-
native treatment provisions may be implemented.
Treatment changes should be patient-centered and
consider individual health needs.
 Changes to standard care were a source of stress and
anxiety for many patients. During emergency or pan-
demic situations, it is important to continue with
shared decision-making and to include patients in
decisions that are made about their health care.
 Health care professionals require education about PA
so that changes made to treatment or care during
emergency situations are evidence-based.
 Where treatment changes are required due to limited
capacity within the health care service, alternative options
such as self-administration of injections could be sup-
ported by adequate training to ensure patient safety.
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